Dipeptide

Other Names

2,5-diketopiperazine (for cyclized form)cyclic dipeptidediketopiperazine (cyclic dipeptide form)dipeptidestwo-amino acid peptide

Synopsis

Dipeptides: A Comprehensive Reference

1. Identity, Chemical Definition, and Classification

A dipeptide is an organic compound derived from two amino acids. The constituent amino acids can be the same or different; when different, two isomers of the dipeptide are possible, depending on the sequence. The bond forms between the carboxyl group of one amino acid and the amino group of another. This peptide bond is a covalent bond formed as two amino acids are joined together through dehydration synthesis, a process in which a water molecule is removed as a byproduct to link monomers together.

Several dipeptides are physiologically important, and some are both physiologically and commercially significant. Even though they are the smallest peptides, dipeptides and tripeptides can be biologically active or show specific properties, or, as digestion products of proteins, function as sources of amino acids. Four hundred different dipeptides can be formed when connecting the 20 proteinogenic amino acids, and most of them if not all have been detected in nature.

Dipeptides are broadly categorized into two structural classes:

Linear dipeptides: The most common form, consisting of a standard amide (peptide) bond between two amino acid residues, retaining a free N-terminus and a free C-terminus.
Cyclic dipeptides (2,5-diketopiperazines, DKPs): The 2,5-diketopiperazines (DKPs), the smallest cyclic dipeptides, formed from the double condensations of two α-amino acids, are abundant in nature and possess a six-membered piperazine rigid backbone. Cyclodipeptides (CDPs) or 2,5-diketopiperazines (DKPs) can exert a variety of biological activities and display pronounced resistance against enzymatic hydrolysis as well as a propensity towards self-assembly into gels, relative to their linear-dipeptide counterparts.

Physical Properties

Dipeptides are white solids. Many are far more water-soluble than the parent amino acids. For example, the dipeptide Ala-Gln has a solubility of 586 g/L—more than ten times the solubility of glutamine alone (35 g/L). This enhanced solubility is one of the primary reasons dipeptides are exploited in parenteral nutrition and pharmaceutical formulations.

2. Natural Sources and Occurrence

Dipeptides are produced from polypeptides by the action of the hydrolase enzyme dipeptidyl peptidase. Dietary proteins are digested to dipeptides and amino acids, and the dipeptides are absorbed more rapidly than the amino acids, because their uptake involves a separate mechanism.

Nutritionally significant dipeptides are found across the animal kingdom. The most extensively studied are the histidine-containing dipeptides (HCDs):

Carnosine (β-alanyl-L-histidine): Carnosine is a dipeptide composed of the non-proteinogenic amino acid beta-alanine and the essential amino acid L-histidine. It is found in the human body not only in relatively high millimolar concentrations in excitable tissues (skeletal muscle and brain) but also in smaller amounts in other tissues (gastrointestinal tract, kidney, liver, adipose tissue, and heart). Dietary intake of carnosine primarily comes from animal-based foods, such as beef (containing 14 mg to 1 g per 100 g), chicken, and fish, as it is absent in plant sources.
Anserine (β-alanyl-1-methyl-L-histidine): It was noticed that most bird muscles do not contain carnosine. Instead, anserine was identified in goose and chicken muscles and was named after the former (anser is Latin for goose).
Ophidine/Balenine (β-alanyl-Nτ-methyl-histidine): Ophidine (beta-alanyl-3-methylhistidine) is the third in the family of beta-alanyl dipeptides. While ophidine is present in large quantities in meat from most whales and also in reptiles, it may only be found in low amounts in most other meats and in fish.

Taurine, carnosine, anserine, and creatine are absent from plants, and hydroxyproline is negligible in many plant-source foods.

In plants, dipeptides were historically associated with nitrogen storage and mobilization; however, they are also reported to act as antioxidants, signaling molecules, protein regulators, and modulators of microbial communities. Naturally occurring dipeptides are categorized as proteinogenic and non-proteinogenic linear dipeptides and cyclic dipeptides. In plants, proteinogenic dipeptides are known to be generated during protein degradation, where short peptides are cleaved by dipeptidyl peptidases (DPPs), including organellar oligopeptidase, cathepsin B, and Nudix hydrolase 3.

Cyclic dipeptides are widely produced by microorganisms. Cyclic dipeptides (or 2,5-diketopiperazines or 2,5-DKPs) are a large class of natural products associated with several biological properties, including antibiotic, antifungal, antiviral, anticancer, and herbicidal activities. These smallest cyclic peptides are produced by bacteria, fungi, plants, and animals. Notably, barettin (cyclo-[(6-bromo-8-en-tryptophan)-arginine]) is a cyclic dipeptide from the marine sponge Geodia barretti.

3. Traditional and Historical Use

The term "dipeptide" as a chemical class was not identified until the late 19th and early 20th centuries, and traditional cultures used foods rich in dipeptides without knowledge of their chemical identity. The history of scientific discovery, however, is well-documented and closely intertwined with the history of meat science and biochemistry.

Discovery of Carnosine

Carnosine was first discovered and reported in 1900 by Russian chemists Gulewitsch and Amiradzibi, who were interested in identifying nitrogen-containing non-protein compounds in meat extract. In his studies of nitrogen contents in samples of minced meat, Gulevich noticed that the total content of organic nitrogen was significantly greater than the sum of protein nitrogen and nitrogen of all extracted components of muscular tissue known at that time. He suggested that there were unidentified nitrogen-containing compounds in muscular tissue. Later, he managed to isolate these compounds from muscle extract. Because this substance was isolated from minced meat, it was given the name "carnosine" (from Latin term caro, carnis — meat).

In 1900, the Russian biochemist W. Gulewitsch discovered an abundant substance in the skeletal muscle of cattle and named this substance carnosine after "caro" or "carnis" (meaning meat in Latin), which was identified in 1918 to be a dipeptide, β-alanyl-L-histidine.

A variety of biological effects of carnosine were demonstrated in patients by Russian physiologists and physicians before World War II. While early interest in carnosine was given because of its role in muscle cell metabolism and athletic performance, it has more recently gained attention for its potential application in several chronic diseases.

Dipeptides in Parenteral and Clinical Nutrition

The use of dipeptides as a source for certain amino acids as a component of mixtures or solutions for artificial nutrition has been known for decades. The use of such dipeptides is especially appropriate if the free amino acids to be administered are poorly soluble in water, such as cystine, tyrosine, tryptophan, valine, leucine, or isoleucine, or are not stable in aqueous solution, such as glutamine or cysteine. The dipeptide L-alanyl-L-glutamine (Ala-Gln) emerged as the clinical solution to the instability of free glutamine in standard total parenteral nutrition (TPN) solutions, representing one of the first systematic clinical applications of synthetic dipeptides.

Dipeptides in Traditional Food Cultures

Long before the chemistry of dipeptides was known, cultures worldwide consumed concentrated sources of histidine-containing dipeptides through traditional food practices. Red meat—particularly beef and game—consumption throughout hunter-gatherer and agricultural civilizations delivered carnosine and related compounds to the diet. Consumption of 30 g dry beef can fully meet daily physiological needs of the healthy 70-kg adult human for taurine and carnosine, and can also provide large amounts of creatine, anserine, and 4-hydroxyproline to improve human nutrition and health.

4. Key Constituents, Active Compounds, and Mechanisms of Action

4.1 Histidine-Containing Dipeptides (HCDs)

The HCDs — carnosine, anserine, and ophidine — share a core β-alanyl-histidine scaffold and collectively exert several well-characterized biological activities:

pH Buffering: The biochemical properties of carnosine include pH-buffering, metal-ion chelation, and antioxidant capacity as well as the capacity to protect against formation of advanced glycation and lipoxidation end-products. Carnosine is characterized by three ionizable groups: the carboxylic group (pKa 2.77), the amino group of the β-alanine residue (pKa 9.66), and the imidazole ring in histidine (pKa 6.83), with the pKa of the whole molecule being 8.25. This pKa places carnosine well within the physiological buffering range of muscle during high-intensity exercise.
Antioxidant Activity: In recent years, antioxidant peptides have received much attention because of their ability to scavenge free radicals, inhibition of lipid peroxidation, chelation of transition metal ions, as well as their additional nutritional value. Among them, dipeptides are attracting much interest as post-amino acids, which have residues in common with amino acids, but also have different physiological properties and functions from those of amino acids. Especially, dipeptides containing moieties of several amino acids (tryptophan, tyrosine, histidine, cysteine, and methionine) possess potent antioxidant activity.
Antiglycation: Carnosine exerts a wide range of biological activities, including antioxidant, anti-inflammatory, anti-glycation, metal-chelating, and neuroprotective properties. Mechanistically, it acts by inhibiting the production of advanced glycation end products (AGEs), buffering cellular pH, and regulating intracellular nitric oxide signaling and mitochondrial function.
Anti-inflammatory and Immunomodulatory: Carnosine's well-demonstrated multimodal mechanism of action includes the detoxification of reactive oxygen and nitrogen species, the down-regulation of the production of pro-inflammatory mediators, the inhibition of aberrant protein formation, and the modulation of cells in the peripheral (macrophages) and brain (microglia) immune systems.
In vitro antioxidant specificity: Carnosine inhibited lipid peroxidation and oxidative modification of protein in muscle tissue prepared from rat hind limb homogenates exposed to Fenton reactant (Fe²⁺, H₂O₂)-generated free radicals. The minimum effective concentrations of carnosine for lipid and protein oxidation were 2.5 and 1 mM, respectively. Histidine and beta-alanine, active components of carnosine, showed no individual effect towards inhibiting either lipid or protein oxidation — indicating that the intact dipeptide structure is necessary for these specific effects.

4.2 The Glutamine Dipeptide: L-Alanyl-L-Glutamine (Ala-Gln)

In vivo studies in humans and animals provide firm evidence that a synthetic glutamine-containing dipeptide, L-alanyl-L-glutamine (Ala-Gln), is readily hydrolyzed following its intravenous administration. The dipeptide form exploits the superior aqueous solubility and thermal stability of the Ala-Gln molecule compared to free glutamine, making it suitable for heat-sterilized parenteral solutions. Once in the body, it is rapidly cleaved to its component amino acids by tissue dipeptidases.

4.3 Cyclic Dipeptides (Diketopiperazines)

The 2,5-DKP motif is the simplest cyclic form of peptides, widespread in nature, resulting from the assembling of two amino acids by nonribosomal peptide synthetases or by cyclodipeptide synthases. The formation of two peptide bonds in DKPs is catalyzed by two major enzymes, the nonribosomal peptide synthetases (NRPSs, >100 kDa) and cyclodipeptide synthases (CDPSs, 30 kDa). DKP dipeptides are endowed with diverse pharmacological properties, such as antimicrobial, insecticidal, antiviral, and nematicidal activities.

4.4 Intestinal Absorption Mechanism: The PepT1 Transporter

The mechanism by which dietary dipeptides are absorbed is well characterized at the molecular level and is fundamental to understanding their superior bioavailability relative to free amino acids:

Human peptide transporter 1 (PEPT1) is an uptake transporter with a major role in the absorption of dietary di- and tripeptides from the small intestinal lumen. It is a high-capacity, low-affinity (KM of 0.2–10 mM), proton-coupled cotransporter of diverse di- and tripeptides and peptidomimetic substrates, and is primarily expressed on the apical microvilli of enterocytes in the small intestine, with lower expression in epithelial cells in the kidney proximal tubule.

PepT1 plays a crucial role in the absorption of small peptides including not only more than 400 different dipeptides and 8,000 tripeptides digested from dietary proteins but also a repertoire of structurally related compounds and drugs.

Experimental findings demonstrate that PEPT1 is responsible for at least 80% of glycylsarcosine (GlySar) uptake during studies using in vitro intestinal rings and in situ single-pass intestinal perfusions.

There is now compelling evidence showing that dietary proteins are absorbed as di- and tripeptides rather than as free amino acids. This absorption process is carried out by the intestinal brush border transporter PepT1, which transfers peptides from a region of low (intestinal lumen) to a region of high (enterocyte cytoplasm) dipeptidase activity. Therefore, PepT1 appears to be essential for the efficient absorption of dietary proteins, and thus for nitrogen supply to the organism.

A secondary transporter, PEPT2, handles renal reabsorption: PepT1 is located in the brush border membrane of the intestinal epithelium and transfers the nutritional peptides from the small intestinal lumen into intestinal absorptive cells (enterocytes). PepT2 expressed in the renal tubules is involved in their re-adsorption from primitive urine.

5. Scientific Evidence by Area of Use

5.1 Athletic Performance and Skeletal Muscle

The most extensively investigated dipeptide in the context of sports nutrition is carnosine. Its precursor β-alanine is supplemented to raise muscle carnosine levels, as carnosine itself is partly hydrolyzed in the gut before reaching muscle. However, direct carnosine supplementation has also been studied.

Beta-alanine is one of the most used sports supplements worldwide, as it improves muscle performance in active athletes, specifically by increasing the concentration of carnosine in the muscles. It is recommended for this purpose by the International Society of Sports Nutrition (ISSN).

A total of 76 clinical trials were found using search terms carnosine and supplementation, most of them related to carnosine muscle content and physical capacity/exercise in health. An additional 14 clinical trials and one systematic review with meta-analysis were identified in PubMed by search terms carnosine, aging, human. A limited number of clinical studies were related to diseases, mostly diabetes and/or obesity.

Evidence strength: The role of muscle carnosine as an intracellular pH buffer during high-intensity exercise is mechanistically well-established and supported by multiple randomized controlled trials (RCTs). The evidence for carnosine itself (rather than its precursor β-alanine) directly improving athletic performance in humans is more preliminary, given that oral carnosine is partly cleaved in the small intestine by carnosinases before reaching systemic circulation.

5.2 Antioxidant Defense and Oxidative Stress

Carnosine, its metabolite N-acetylcarnosine, and the synthetic derivative zinc-L-carnosine have recently been gaining popularity as supplements in human medicine. These molecules have a wide range of effects — principally with anti-inflammatory, antioxidant, antiglycation, anticarbonylation, calcium-regulatory, immunomodulatory and chelating properties.

In the last 50 years different studies have assessed the role and function of carnosine through numerous in vitro, in vivo, and clinical studies, demonstrating the multimodal mechanism of action of this dipeptide that includes anti-aggregant, antioxidant, and anti-inflammatory activities.

Evidence strength: The antioxidant activity of carnosine is robustly established in in vitro and animal models. Clinical evidence in humans remains more limited; while mechanistic data are strong, the number of large, well-powered RCTs in humans specifically evaluating oxidative stress endpoints is small.

5.3 Neurology and Cognitive Function

Carnosine is a neuroprotective dipeptide consisting of beta-alanine and L-histidine. It demonstrates a number of useful features, including stimulation of brain and muscle microcirculation and a rejuvenating effect on cultured cells. Its activity is based on its antioxidant and antiglycating action that, in addition to heavy metal chelation and pH-buffering ability, makes carnosine an essential factor for preventing neurodegeneration and accumulation of senile features.

Evidence showed that carnosine supplementation had a beneficial impact in the prevention of sarcopenia, the preservation of cognitive abilities and the improvement of neurodegenerative disorders.

Brain aging and neurodegenerative disorders have received particular attention, as a marked reduction in carnosine levels has been described in these conditions.

However, a 2025 RCT examining cognitive outcomes in prediabetes and well-controlled type 2 diabetes found mixed results. In total, 42 adults (23 males and 19 females) completed the trial. There were no differences in participant anthropometry or cognitive functioning between carnosine and placebo groups at baseline. After the 14-week supplementation period, there were no differences between carnosine and placebo groups in change and follow-up values for any cognitive measures including Stroop, Digit Symbol Substitution Test, Trail Making A/B or CANTAB.

The dosage (2 g) and duration (14 weeks) of carnosine supplementation used in this trial may also have been insufficient to affect cognitive measures to an extent detectable within the constraints of the sample size and statistical power.

Although researchers reported improved memory in elderly populations and improved delayed recall following supplementation among individuals with and without mild cognitive impairment assessed using the Wechsler Memory Test (WMS-2), these effects could not be attributed solely to carnosine. The same systematic review identified other key gaps in the evidence, namely the reliance on relatively brief global tests of cognition following carnosine supplementation.

Evidence strength: Preliminary and inconsistent. Preclinical data are promising, but human RCTs are small, short in duration, and have produced conflicting results. Larger, longer, and better-powered trials are needed.

5.4 Metabolic Disease: Type 2 Diabetes and Cardiometabolic Health

Carnosine's activity has been investigated in experimental models of cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and neurodegenerative disorders, such as cerebral ischemia and Alzheimer's disease. Researchers examined the protective role that carnosine could exert in the context of T2DM, CVD, and AD, which share common pathogenic mechanisms including oxidative stress, inflammation, and aggregation phenomena.

The neuroprotective effects of carnosine combined with its antioxidant and cardioprotective activity suggests that this dipeptide might represent an ideal pharmacological tool for future clinical studies in patients with diabetes where both cerebrovascular and cardiovascular complications often coexist.

Participants in one RCT were instructed to take either cornstarch (placebo) or carnosine capsules (2 g daily) for up to 12 weeks. Cognitive ability was assessed using the Cognition test battery, which consists of ten individual tests known to engage specific brain systems and covering a range of cognitive domains. Speed, accuracy, and efficiency were obtained for the whole battery as well as for each of the ten individual tests. Participant testing occurred at baseline, prior to randomization, after approximately 6 weeks of supplementation, and after approximately 12 weeks of supplementation. Of the 299 participants who were randomized, useable measures were obtained for 242 participants at Follow-up-1 and 231 at Follow-up-2. In this study population, carnosine supplementation selectively improved high-level cognitive performance in young individuals.

Evidence strength: Evidence is preliminary. Mechanistic rationale is strong, but human RCTs are small, heterogeneous in design, and have shown mixed results. Additional well-powered trials are needed before conclusions can be drawn.

5.5 Clinical Nutrition: L-Alanyl-L-Glutamine in Parenteral Nutrition

The dipeptide L-alanyl-L-glutamine (Ala-Gln) has the most robust human clinical evidence base of any individual dipeptide in the nutritional supplementation context, particularly in critical care and surgical populations.

In vivo studies in humans and animals provide firm evidence that L-alanyl-L-glutamine (Ala-Gln) is readily hydrolyzed following its intravenous administration. The results indicate a safe and efficient use of Ala-Gln as a source of free glutamine in parenteral nutrition. In clinical studies, nitrogen balance was more positive in catabolic patients receiving a peptide-supplemented solution than in control patients given isonitrogenous, isoenergetic total parenteral nutrition. Muscle glutamine concentrations were markedly decreased in the control groups.

A meta-analysis reviewed 14 RCTs (N = 587): The results showed that glutamine dipeptide significantly reduced the length of hospital stay by around 4 days in the form of alanyl-glutamine (weighted mean difference [WMD] = −3.84; 95% confidence interval [CI] −5.40, −2.28).

A double-blind, randomized, controlled trial at multiple surgical ICU centers: Subjects (n = 59) received isocaloric/isonitrogenous parenteral nutrition, providing 1.5 g/kg/d standard glutamine-free amino acids (STD-PN) or 1.0 g/kg/d standard amino acids + 0.5 g/kg/d glutamine dipeptide (GLN-PN). This randomized, double-blind, controlled clinical trial suggests that supplementation of PN with alanyl-GLN dipeptide was well tolerated, decreased nosocomial infections, and improved organ function indices in adult patients requiring both PN and prolonged SICU care after cardiac, abdominal vascular, and colonic surgery.

However, not all trials have been positive: Glutamine dipeptide-supplemented parenteral nutrition did not alter infection rates following pancreatic necrosis surgery but significantly decreased infections in SICU patients after cardiac, vascular, and colonic surgery.

In one controlled double-blind study in autologous transplant patients: Forty patients were randomized; 21 into the glutamine and 19 into the placebo arm. Glutamine patients had less days with diarrhoea (3.3 ± 4.0 vs 4.3 ± 3.0, P = 0.03), but they had more severe oral mucositis and spent more days on opioids and left hospital later than placebo patients.

Evidence strength: Moderate to strong for reduction of hospital length of stay and nitrogen balance in surgical and critically ill patients. Evidence is heterogeneous; some subgroups show benefit while others show neutral or mixed outcomes. Guidelines from multiple critical care societies have recognized glutamine dipeptide supplementation, though its use remains context-specific.

5.6 Cyclic Dipeptides: Antimicrobial and Antineoplastic Potential

In bacteria, cyclo(L-Leu-L-Pro) (cLP) is often associated with other DKPs to serve as a defense element against other microorganisms and/or as a regulator of bacterial growth. cLP plays a role in quorum-sensing and functions as an anticariogenic and antifungal agent. The interest in cLP for combatting certain parasitic diseases, such as malaria, and cancers is discussed. The capacity of cLP to interact with CD151 and to down-regulate the expression of this tetraspanin can be exploited to reduce tumor dissemination and metastases.

The DKP motif is considered important to the design of anticancer agents. As well as representing intrinsically bioactive natural products, 2,5-DKPs provide useful fragments for molecular drug design for a wide variety of biomedical applications. Their antimicrobial activity has been of particular interest, with antimicrobial resistance being predicted to become a greater burden on public health than cancer by 2050.

Evidence strength: Predominantly preclinical (in vitro and animal studies). Cyclic dipeptides from natural sources have demonstrated significant biological activities in laboratory settings, but clinical translation to human therapeutics or dietary supplements remains at an early stage. No robust human RCTs specific to cyclic dipeptides as dietary supplements have been identified in the peer-reviewed literature.

6. Body Systems and Health Areas of Association

Musculoskeletal System: Carnosine and anserine in high concentrations in skeletal muscle; pH buffering during exercise; antioxidant protection of myofibers; evidence of beneficial impact in the prevention of sarcopenia.
Nervous System: Carnosine is present at particularly high concentrations in the brain (0.7–2.0 mM) as well as in cardiac and skeletal muscles (up to 20 mM). Neuroprotective properties are under investigation for neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and stroke.
Gastrointestinal Tract: PepT1-mediated absorption of dietary dipeptides is the primary route of nitrogen assimilation from protein. Colonic expression of PEPT1 has been noted in patients suffering from short bowel syndrome and inflammatory bowel disease. Dipeptides are found to stimulate the release of gastrin from G-cells in the stomach.
Renal System: In the kidney, PEPT1 reabsorbs peptides from the primary filtrate in the proximal tubule, in conjunction with a similar transporter, PEPT2.
Cardiovascular System: Carnosine has demonstrated beneficial outcomes in heart failure, stroke, and type 2 diabetes in humans, though these results require further study.
Metabolic/Endocrine System: Antiglycation activity of carnosine is relevant to diabetes management. Inhibition of AGE formation represents a potential benefit in insulin resistance and type 2 diabetes-related complications.
Immune System: PEPT1 also has significance in its ability to transport therapeutic agents and because of its potential as a target for anti-inflammatory therapies. Dipeptide-stimulated innate immune signaling in the gut is a documented area of research.

7. Dosage Forms and Dosages Reported in Studies

Carnosine — Oral Supplementation

Participants in one RCT were instructed to take carnosine capsules at 2 g daily for up to 12 weeks.
Earlier Japanese studies administered carnosine at doses ranging from 250 mg to 1 g daily, with some studies using a combination of carnosine and anserine.
Oral carnosine was safe and well tolerated up to a dose of 10 g. At doses of 15 g, the frequency of adverse events became unacceptably high, with 77% of participants experiencing side effects, most commonly headache (43.5%), nausea (21.7%) and paraesthesia (21.7%).
Long-term dosing at 5 g twice daily did not result in any adverse events.

L-Alanyl-L-Glutamine (Ala-Gln) — Parenteral

Subjects received parenteral nutrition providing 0.5 g/kg/d glutamine dipeptide (GLN-PN).
Patients received 30 g of alanyl-glutamine dipeptide (Dipeptiven; Fresenius-Kabi) intravenously from day +1 to day +14 or to discharge.
In one RCT, patients received Gln-supplemented TPN containing L-alanyl-L-glutamine dipeptide at 0.5 g/kg per day.

Dosage Forms Available

The applications for dipeptides are diverse. Some dipeptides such as aspartame have found use as artificial sweeteners in the food industry while other dipeptides are being used as supplements in cell culture media. In the area of drug development, dipeptides and tripeptides are attractive due to cost-effectiveness, possibility of oral administration, low molecular weight, and simplicity for structure-activity studies. Commercial forms include:

Oral capsules or tablets (carnosine, anserine, carnosine-anserine combinations)
Parenteral infusion solutions (alanyl-glutamine, e.g., Dipeptiven®)
Functional food ingredients and protein hydrolysates
Cell culture media supplements (Ala-Gln, due to its enhanced solubility)

8. Safety Considerations and Interactions

Carnosine — Safety Profile

Oral carnosine was safe and well tolerated up to a dose of 10 g. At doses of 15 g, 77% of participants experienced side effects, most commonly headache (43.5%), nausea (21.7%) and paraesthesia (21.7%). While pharmacokinetic profiles varied between individuals, peak plasma concentrations occurred within the first hour of dosing. Little circulating carnosine was detectable beyond 4 h. Brain carnosine concentration increased at 1 h post-dose but reverted to baseline values by 5 h. Long-term dosing at 5 g twice daily did not result in any adverse events.

Since carnosine's discovery more than 100 years ago, a plethora of in vivo preclinical studies have been carried out; however, there is still substantial heterogeneity regarding the route of administration, the dosage, the duration of the treatment, and the animal model selected, underlining the urgent need for "coordinated/aligned" preclinical studies laying the foundations for well-defined future clinical trials.

Glutamine Dipeptide (Ala-Gln) — Safety and Interactions

Results indicate a safe and efficient use of Ala-Gln as a source of free glutamine in parenteral nutrition. Clinically, the parenteral dipeptide is well tolerated when administered at standard dosages. The mixed clinical results across different patient populations — for example, in autologous transplant patients — indicate that the clinical context significantly modulates the benefit-risk profile.

Cyclic Dipeptides — Safety

DKP dipeptides are endowed with diverse pharmacological properties. Because cyclic dipeptides arise from normal protein digestion and are present in fermented foods and common foodstuffs, they are considered generally safe at the concentrations encountered through normal dietary exposure. However, no specific clinical safety trials for isolated cyclic dipeptide supplementation in humans have been identified in the peer-reviewed literature.

PepT1-Related Drug Interactions

PepT1 has an enormous range of substrates, including more than 400 different dipeptides and 8,000 tripeptides, as well as a repertoire of structurally closely related compounds and drugs, including the anticancer agent bestatin, β-lactam antibiotics, angiotensin-converting enzyme (ACE) inhibitors for hypertension, anti-virus drug valacyclovir, and L-DOPA-L-Phe. Competitive interactions at the PepT1 transporter between dietary dipeptides and peptidomimetic drugs are a theoretically relevant consideration, though the clinical significance of these interactions at typical dietary or supplemental dipeptide intakes remains to be fully characterized.

Senesitivity of HCD Levels to Diet

Fasting and a high-protein diet have each been shown to increase the levels of PepT1 mRNA and protein in the brush border of intestinal cells, which may upregulate the absorption capacity for dipeptides during high-protein dietary periods or supplementation protocols.

References

Health Conditions

Health conditions that Dipeptide may help support.

No conditions available.

Body Systems

Body systems that Dipeptide may help support.

No body systems available.